Sign inJoin waitlistJoin the waitlist

Kent Mouw

Assistant Professor · University of Washington School of Medicine

Credentials: · · · ·

History

University of Washington School of Medicine
Present

Radiation Oncology
Mass General Brigham
2011–2015
Preliminary or Transitional Year
2010–2011
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
2006–2010

Research

DNA Damage and Repair Biomarkers of Immunotherapy Response
Review · Cancer Discovery · 2017 · First of 4 authors · 541 citations
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
Cancer Discovery · 2014 · 525 citations
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Nature Genetics · 2017 · 432 citations

Paul Nguyen
29 papers
Eli Van Allen
25 papers
VM
Vinayak Muralidhar
23 papers · 23 as a resident
Neil Martin
20 papers
Brandon Mahal
19 papers · 19 as a resident
Joaquim Bellmunt
17 papers
Martin King
17 papers · 2 as a fellow
Alan D’Andrea
15 papers
Jason Efstathiou
15 papers
Peter Orio
15 papers
David Yang
14 papers · 7 as a resident
Anthony D'Amico
13 papers

Grants

Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer
National Cancer Institute · R01
Contact PI · $1.5M · Dana-Farber Cancer Inst
2024–2029
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer
National Cancer Institute · R01
PI · $2.2M · Dana-Farber Cancer Inst
2024–2029
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
National Cancer Institute · R01
Contact PI · $2.1M · Dana-Farber Cancer Inst
2022–2027
Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer
National Cancer Institute · R21
Contact PI · $452.9K · Dana-Farber Cancer Inst
2024–2026

Clinical trials

Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
2018–2025
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027